Zenapax

Zenapax: description of the drug and its use

Zenapax is an immunosuppressive drug manufactured in Switzerland by the Hoffmann-La Roche company. The active substance is Daclizumab, which is used to prevent acute kidney allograft rejection in combination with cyclosporine and corticosteroids.

The dosage form of Zenapax is a concentrate for the preparation of an infusion solution of 25 mg/5 ml. The drug is available only with a doctor's prescription.

Indications for the use of Zenapax are limited to the prevention of renal allograft rejection. Contraindications include hypersensitivity to daclizumab and breastfeeding.

Various side effects may occur when using Zenapax. In particular, headaches, dizziness, insomnia, tremors, blurred vision and others may occur from the nervous system and sensory organs. From the cardiovascular system and blood, arterial hypertension or hypotension, tachycardia, bleeding or thrombosis may occur. From the genitourinary system, dysuria, oliguria, edema and other pathologies may be observed. In addition, various reactions may occur from the musculoskeletal system, skin and other organs and systems.

The interaction of Zenapax with other solutions is pharmaceutically incompatible. There is no data on drug overdose. When using Zenapax in old age (over 65 years) and during pregnancy, special caution must be taken. Women of childbearing potential are advised to use adequate contraception during treatment and for 4 months after its completion.

Thus, Zenapax is an effective immunosuppressive drug that can be used to prevent renal allograft rejection. However, when using it, it is necessary to take into account the possibility of side effects and interactions with other drugs, and also to exercise caution in old age and during pregnancy.